OncoMatch/Clinical Trials/NCT06479239
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
Is NCT06479239 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies EGFR FPBMC for pancreas cancer.
Treatment: EGFR FPBMC — The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with metastatic or unresectable pancreas cancer. Participants receive 8 twice weekly doses and then 8 more doses every 2 weeks of EGFR FPBMC by intravenous infusion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy (gemcitabine, 5FU, capecitabine, albumin-bound paclitaxel)
Therapy should consist of either a gemcitabine, 5FU-based (including capecitabine) or albumin-bound paclitaxel-based regimen
Cannot have received: investigational agent
Treatment with investigational agent within 3 weeks prior to registration
Lab requirements
Blood counts
absolute neutrophil count >= 500/mm3; absolute lymphocyte count >= 400/mm3; platelets >= 75,000/mm3; hemoglobin >= 8 g/dl
Kidney function
serum creatinine < 2.0mg/dl or calculated/measured creatinine clearance >= 50 ml/min
Liver function
bilirubin <= 2 mg/dl; ast and alt <= 5.0 x uln
Cardiac function
no uncontrolled angina or severe ventricular arrhythmias; no clinically significant pericardial disease; no history of myocardial infarction (mi) in the last year before registration; no class 3 or higher new york heart association congestive heart failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Virginia · Charlottesville, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06479239 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages